Search - tctmd.com

Displaying 301 - 320 of 361

Sort: Relevancy | Date

Presentation TCT 2013

FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-eluting Stent: Update on the FIH, TARGET I, and TARGET II Trials

Presenter: Bo Xu

October 27, 2013

Presentation TCT 2013

Two-year Clinical Outcomes Of Primary Stenting Of Totally Occluded Native Coronary Arteries III (PRISON III): A Randomized Comparison Of Sirolimus-Eluting Stent Implantation Wit...

Presenter: Koen Teeuwen, Ben Van den Branden, Jacques Koolen, Jose Henriques, Jan Tijssen, Hans Kelder, Ren? Van der Schaaf, Paul Vermeersch, Benno Rensing, Maarten j. Suttorp

January 31, 2013

Presentation TCT 2013

THREE YEAR FOLLOW UP OF A RANDOMIZED COMPARISON OF NOBORI, BIOLIMUS A9 ELUTING STENT(BES) WITH CYPHER, SIROLIMUS ELUTING STENT(SES) FOR CORONARY REVASCULARIZATION IN JAPANESE...

Presenter: Takeshi Kimura, Toshiya Muramatsu, Masashi Iwabuchi, Shigeru Saito, Yasuhiko Hayashi, Yuji Ikari, Kenshi Fujii, Shinsuke Nanto, Naoto Inoue, Atsuo Namiki, Haruo Hirayama, Osamu Doi, Mitsuo Kashida, Junji Yajima, Kazuaki Mitsudo

January 31, 2013

$The impact of sirolimus-eluting stent and evelolimus-eluting stent on the in-stent restenosis and stent fracture; evaluating peri-stent contrast staining lesions after...$

Presentation TCT 2013

The impact of sirolimus-eluting stent and evelolimus-eluting stent on the in-stent restenosis and stent fracture; evaluating peri-stent contrast staining lesions after...

Presenter: Tahei Ichinohe, Kazushige Kadota, Haruki Eguchi, Seiji Habara, Hiroyuki Tanaka, Takeshi Tada, Yasushi Fuku, Naoki Oka, Hiroyuki Yamamoto, Satoki Fujii, Tsuyoshi Goto, Kazuaki Mitsudo

January 31, 2013

Presentation TCT 2013

The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated With The Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and Paclitaxel-Eluting...

Presenter: Aris Moschovitis, Giulio Stefanini, Michael Magro, Lorenz R?ber, Bindu Kalesan, Masanori Taniwaki, Joost Daemen, Peter Wenaweser, Ron Van Domburg, Bernhard Meier, Peter Juni, Patrick Serruys, Stephan Windecker

January 31, 2013

Presentation TCT 2013

Seven-year Clinical Outcomes of Sirolimus-Eluting Stent Versus Bare-Metal Stent; A Matched Analysis From A Real World, Single Center Registry

Presenter: Jin-Sung Lee, Yoon-Jung Choi, Ung Kim, Jong-Seon Park, Jang-Won Son, Sang-Hee Lee, Dong-Gu Shin, Young-Jo Kim

January 31, 2013

Presentation TCT 2013

NOYA I: A Prospective Randomized Trial of the Biodegradable Polymer NOYA Sirolimus-Eluting Stent Compared with the Durable Polymer FIREBIRD 2 Sirolimus-Eluting Stent in Patients...

Presenter: Bo Xu, Kefei Dou, Yuejin Yang, Shuzheng Lu, Lefeng Wang, Haichang Wang, Zhanquan Li, Lei Wang, YunDai Chen, Yong Huo, Ajay Kirtane, Run-Lin Gao

January 31, 2013

Presentation TCT 2013

LONG TERM OUTCOME OF PATIENTS WITH BIFURCATED LESIONS RANDOMIZED TO SIROLIMUS OR EVEROLIMUS ELUTING STENT: THE SEA-CORP BC STUDY

Presenter: Francesco Burzotta, Pan Manuel, Trani Carlo, Medina Alfonso, SU?REZ DE LEZO Jos?, Niccoli Giampaolo, Romero Miguel, Porto Italo, Mazuelos Francisco, Leone Antonio Maria, Martin Pedro, Valentina Coluccia, SU?REZ DE LEZO Javier, OJEDA Soledad, Crea Filippo

January 31, 2013

Presentation TCT 2013

Intimal Hyperplasia and Vascular Remodeling after Everolimus-eluting and Sirolimus-eluting Stent Implantation in Diabetic Patients. The Randomized Diabetes and Drug-Eluting Sten...

Presenter: Lisbeth Antonsen, Lisette Okkels Jensen, Michael Maeng, Per Thayssen, Evald H?j Christiansen, Knud N?rregaard Hansen, Anne Kaltoft, Henrik Steen Hansen, Leif Thuesen, Jens Flensted Lassen

January 31, 2013

Presentation TCT 2013

Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis

Presenter: Sachin Goel, Wael El-Mallah, Mobolaji Ige, Supriya Gupta, E Murat Tuzcu, Stephen Ellis, Samir Kapadia

January 31, 2013

Presentation TCT 2013

Comparison of Zotarolimus-Eluting stents versus Everolimus –Eluting stents versus Sirolimus-Eluting and in Patients with Long Coronary Artery Lesions Assessed by Volumetric...

Presenter: Young-Rak Cho, Jung-Min Ahn, Soo-Jin Kang, Young-Hak Kim, Won-Jang Kim, Jong-Young Lee, Woo Seok Lee, Gyung-Min Park, Seung-Jung Park

January 31, 2013

Presentation TCT 2013

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

Presenter: Hironori Kitabata, Joshua Loh, Gabriel Sardi, Salem Badr, Danny Dvir, Israel Barbash, Rebecca Torguson, Kenneth Kent, Lowell Satler, William Suddath, Augusto Pichard, Ron Waksman

January 31, 2013

Presentation TCT 2013

Acute Delivery and Long Term Retention of Sirolimus Nanoparticles Using a Novel Porous Angioplasty Balloon in the Porcine Coronary Model

Presenter: Armando Tellez, Piotr Buszman, Maxwell Afari, Taylor Palmieri, Yanping Cheng, William Rate, Samantha Stone, Gerard Conditt, Yen-Fang Keng, Brendan Bingham, William Baumbach, Darren Sherman, Greg Kaluza, Juan Granada

January 31, 2013

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

Presenter: Suhas Lele

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Patrick Serruys

October 25, 2012

News Conference News TCT 2012

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

October 24, 2012

Advertisement

FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-eluting Stent: Update on the FIH, TARGET I, and TARGET II Trials

Two-year Clinical Outcomes Of Primary Stenting Of Totally Occluded Native Coronary Arteries III (PRISON III): A Randomized Comparison Of Sirolimus-Eluting Stent Implantation Wit...

THREE YEAR FOLLOW UP OF A RANDOMIZED COMPARISON OF NOBORI, BIOLIMUS A9 ELUTING STENT(BES) WITH CYPHER, SIROLIMUS ELUTING STENT(SES) FOR CORONARY REVASCULARIZATION IN JAPANESE...

The impact of sirolimus-eluting stent and evelolimus-eluting stent on the in-stent restenosis and stent fracture; evaluating peri-stent contrast staining lesions after...

The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated With The Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and Paclitaxel-Eluting...

Seven-year Clinical Outcomes of Sirolimus-Eluting Stent Versus Bare-Metal Stent; A Matched Analysis From A Real World, Single Center Registry

NOYA I: A Prospective Randomized Trial of the Biodegradable Polymer NOYA Sirolimus-Eluting Stent Compared with the Durable Polymer FIREBIRD 2 Sirolimus-Eluting Stent in Patients...

LONG TERM OUTCOME OF PATIENTS WITH BIFURCATED LESIONS RANDOMIZED TO SIROLIMUS OR EVEROLIMUS ELUTING STENT: THE SEA-CORP BC STUDY

Intimal Hyperplasia and Vascular Remodeling after Everolimus-eluting and Sirolimus-eluting Stent Implantation in Diabetic Patients. The Randomized Diabetes and Drug-Eluting Sten...

Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis

Comparison of Zotarolimus-Eluting stents versus Everolimus –Eluting stents versus Sirolimus-Eluting and in Patients with Long Coronary Artery Lesions Assessed by Volumetric...

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

Acute Delivery and Long Term Retention of Sirolimus Nanoparticles Using a Novel Porous Angioplasty Balloon in the Porcine Coronary Model

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content